1 Title: Safety and efficacy of rapamycin on healthspan metrics after one year: PEARL Trial 2 Results 3 Authors: Girish Harinath^{1,2}, Virginia Lee^{1,2}, Andy Nyquist¹, Mauricio Moel¹, Jesper Hagemeier¹, 4 5 Stefanie L. Morgan^{1,2,*}, Anar Isman¹, Sajad Zalzala¹ 6 7 Affiliations: 8 ^{1.} AgelessRx, Ann Arbor MI, USA 9 ^{2.} Division of Research and Applied Sciences, AgelessRx, Ann Arbor MI, USA 10 ^{3.} Data and Analytics Division, AgelessRx, Ann Arbor MI, USA 11 * Corresponding author 12 13 Corresponding author: Stefanie L Morgan, stefanie@agelessrx.com 14 15 **Abstract**: Rapamycin has been shown to have longevity-enhancing effects in murine models, 16 but clinical data on its gerotherapeutic effects in humans remains limited. We performed a 48-17 week double-blinded, randomized, and placebo-controlled decentralized study (Participatory 18 Evaluation of Aging with Rapamycin for Longevity [PEARL]; NCT04488601; registration date 19 2020-07-28) to evaluate the safety and efficacy of rapamycin in mitigating clinical signs of aging 20 in a normative aging cohort. Participants received 5 or 10 mg / week of compounded 21 rapamycin, or placebo for 48 weeks. Safety, adverse events (AEs) and blood biomarkers were 22 collected. Efficacy was assessed using DEXA scan-based measures and standardized surveys 23 assessing quality of life (QoL) and frailty. We did not detect significant differences in safety 24 blood biomarkers, or moderate to severe AEs between the rapamycin treatment groups and 25 placebo after 48 weeks. We detected dose-dependent (10 mg group) and sex-specific 26 improvements in lean tissue mass, pain, social functioning, overall QoL, and overall 27 osteoarthritis score in females, and in bone mineral content in men. Additionally, some 28 individuals receiving rapamycin experienced significant improvements in body composition 29 metrics that were associated with beneficial changes in gut health and lipid metabolism. We

- 30 conclude that low-dose, intermittent rapamycin administration over the course of 48 weeks is
- 31 safe and induces sex-specific improvements in multiple aspects of healthspan, with the most
- 32 robust improvements in lean tissue mass in women taking 10 mg rapamycin/week. Future work
- 33 will aim to identify biometric signatures of clinical effectiveness to inform personalized
- 34 treatment strategies that more broadly maximize efficacy and minimize side effects.
- 35
- 36 Keywords: rapamycin, aging, healthspan, longevity

37 Introduction

38 Aging is the biggest risk factor for all major chronic diseases, accounting for nearly 70% 39 of human mortality [1-3]. While advancements in medical technologies and public health 40 practices over the past 150 years have led to longer lifespans less shaped by natural selection, 41 the period of disease and disability-free life often referred to as "healthspan" has not kept pace 42 [4]. In conjunction with an epidemic of poor lifestyle habits, this has collectively led to a 43 growing chasm between lifespan and healthspan known as the healthspan gap, which in the 44 United States lasts several decades and is characterized by a high burden of functional disability 45 and age-related diseases (such as type 2 diabetes, osteoarthritis, and Alzheimer's) that often 46 coexist as multi-morbidities [5]. While significant research has historically focused on treating 47 these diseases individually, a growing body of work within translational geroscience explores 48 developing gerotherapeutics that slow the aging process and delay the onset or prevent age-49 related disease altogether [6].

50 The field of translational geroscience has made rapid advancements in recent years, due 51 in large part to strategic utilization of interventions already approved for other conditions by 52 the US Food and Drug Administration (FDA) [7]. By repurposing such drugs for their potential to 53 target the biology of aging and extend healthy longevity, clinical validation is fast-tracked to 54 permit more immediate collection of application-specific efficacy data. Notable among these is 55 rapamycin, which is widely used for its purported longevity and healthspan benefits within the 56 pro-longevity community [8]. While evidence supports a role for rapamycin in improving life-57 and healthspans in preclinical studies [9], little data exists on its clinical efficacy in normative 58 aging humans.

As an FDA-approved small molecule drug, rapamycin is an evolutionarily conserved inhibitor of the mammalian target of rapamycin serine/threonine kinase complex 1 (mTORc1), a known regulator of aging processes [10, 11]. Hyperactivity of mTORC1 has been linked to multiple chronic disease processes in nearly every organ system, while mTORC1 inhibition induced by caloric restriction and rapamycin or its derivatives (rapalogs) has been shown to reliably extend lifespan and healthspan across organisms from yeast to non-human primates [12-21]. Rapamycin-mediated mTORC1 inhibition has demonstrated particular efficacy as a

geroprotective intervention in mice, extending lifespan in heterogeneous genetic backgrounds
across multiple studies from independent labs at multiple dosages, dosing periods, and
regimens, even in elderly animals [14, 16, 18, 21, 22].

69 While rapamycin has demonstrated a more pronounced lifespan-enhancing effect in 70 female than male mice, mitigation or reversal of age-associated changes in multiple organ 71 tissues and the immune system have been observed for both sexes [23-25]. These findings have 72 been reproduced in companion dogs and marmosets, however, clinical data on rapamycin's 73 gerotherapeutic effects in humans remains limited [9, 12, 17, 26]. Given the substantial promise 74 in preclinical data, it is essential to obtain a deeper understanding and clearly define the clinical 75 benefits of rapamycin use for improving healthy aging in the generally healthy, adult population. In particular, it will be important to understand how rapamycin may impact the 76 77 phenotypes of the biological aging process that substantially increases the risk of age-related 78 disease and mortality, such as an accumulation of visceral adipose tissue (VAT) and a loss of 79 lean muscle tissue and bone mass [27-32]. These are some of the most salient and functionally 80 consequential measures of biological aging, which frequently lead to reduced quality of life 81 (QoL), increased pain, and limited mobility, particularly for post-menopausal women [33, 34]. 82 Collectively, this contributes to the marked decline in health that often occurs during this time 83 period [33]. It has been suggested that use of low-dose rapamycin may mitigate these features 84 of the aging process, enhancing healthspan [25, 35, 36].

85 Widespread adoption of rapamycin as a gerotherapeutic has historically been limited by concerns regarding its known impact on immunosuppression, hyperlipidemia, and 86 87 hyperglycemia [37]. However, the vast majority of these effects stem from high, chronically 88 administered doses utilized in severely ill organ transplant or cancer patients, where the clinical 89 aim is inhibition of the immune system or anti-tumorigenic effects. In contrast, as a 90 gerotherapeutic for normative aging populations, low-dose, intermittent rapamycin is revealing 91 promise for minimizing side effects while still mitigating aspects of age-related decline [38-40]. 92 For example, Mannick et al. demonstrated that healthy elderly individuals taking 0.5 mg of a 93 rapalog daily or 5 mg/ week for 6 weeks mitigated age-related immune decline by enhancing 94 the adaptive immune system's response to vaccination [41]. This supports our recent findings

95 from a study of 333 low-dose rapamycin users indicating a high perceived QoL and improved 96 health outcomes compared to non-users [8]. Preliminary data suggest that these effects stem 97 from a partial inhibition of mTORc1 in low-dose rapamycin (rather than the complete inhibition 98 observed at higher doses), which has been demonstrated to mitigate age-related decline by 99 stimulating autophagy, reducing senescent burden, and reducing pro-inflammatory cytokines 100 that drive chronic inflammation [9, 15, 24, 42, 43]. While promising findings such as these have 101 encouraged some physicians to prescribe off-label rapamycin as a therapy to maintain 102 healthspan, there are many open questions that require further study, particularly in a clinical 103 setting.

104 An important gap in the clinical understanding of rapamycin for longevity is that to date, 105 no long-term randomized controlled trials (RCT) have been conducted to explore low-dose, 106 intermittent rapamycin regimens for improving multiple healthspan metrics in normative aging 107 cohorts. The current study, the Participatory Evaluation of Aging with Rapamycin for Longevity 108 (PEARL) trial, aimed to address this gap. PEARL represents the largest and longest clinical study 109 of rapamycin use for healthy aging performed to date. This 48-week double-blinded, 110 randomized placebo-controlled decentralized study evaluated the safety and efficacy of 111 rapamycin in mitigating clinical signs of aging in a generally healthy cohort. Here, we present 112 the first evidence to date, to our knowledge, that low-dose rapamycin administration is safe 113 over the course of 48 weeks and induces sex-specific improvements in lean muscle mass, bone 114 mineral content, aspects of age-related frailty, and overall QoL. Further, we highlight additional 115 benefits observed specifically in rapamycin responders that may offer mechanistic insights into 116 key biological drivers of clinical effectiveness that will be investigated in greater depth in future 117 studies.

118

119 Methods

120 Study design

121 The PEARL study was a decentralized, single-center, prospective, double-blind, placebo-122 controlled trial assessing rapamycin in healthy individuals aged 50-85 years, to determine the 123 safety and efficacy in mitigating aging-related decline (**Supplementary Figure S1**).

124

125 The study was conducted in accordance with the standards of Good Clinical Practice, as 126 defined by the International Conference on Harmonisation and all applicable federal and local 127 regulations. The study protocol was approved by the institutional review board of the Institute 128 of Regenerative and Cellular Medicine in May 2020 (IRCM; approval number IRCM-2020-252). 129

130 Study endpoints

131 The primary endpoints of this study included safety, which included the collection of 132 adverse events (AEs), safety blood biomarkers, and visceral adiposity. Secondary endpoints 133 included efficacy blood biomarkers, DEXA scan-determined lean tissue mass and bone mineral 134 content, and standardized surveys assessing quality of life and frailty.

135

136 Study population

137 Participants were recruited via the AgelessRx online medical platform. Patients were 138 screened for eligibility, and if deemed eligible, informed consent was obtained for participation 139 in the study.

140 Participants were eligible for the study if they were aged between 50 and 85 years at 141 the start of the study, were interested in taking rapamycin off-label, were willing to undergo 142 minimally invasive tests, and were in good health or had well-managed clinically-stable chronic 143 diseases. Participants were excluded from the study if they had anemia, neutropenia, or 144 thrombocytopenia, were premenopausal, were scheduled to undergo major surgery in next 12 145 months, were undergoing or were scheduled to undergo chemotherapy, were scheduled for 146 immunosuppressant therapy for an organ transplant, had impaired wound healing or history of 147 chronic open wound, untreated dyslipidemia, impaired hepatic function, chronic infections 148 requiring ongoing treatment or monitoring (e.g. human immunodeficiency virus/acquired 149 immunodeficiency syndrome, chronic Lyme disease), allergy to rapamycin, clinically-relevant 150 primary or secondary immune dysfunction or deficiency, chronic oral corticosteroid or 151 immunosuppressant medication use, fibromyalgia, chronic fatigue syndrome/myalgic 152 encephalitis, breast implant illness, congestive heart failure, impaired renal function, poorly

controlled diabetes, type I or insulin-dependent type II diabetes, untreated or treated within
the last five years for substance abuse disorder, and untreated or poorly controlled mental
health disorder. Further, those who had taken metformin, rapamycin, or rapalogs were
excluded unless the participant agreed to a 6 month washout period prior to the start of the
trial.

158

159 Treatments

160 Study participants were randomized into three groups: receiving 5 mg of rapamycin, 10 161 mg of rapamycin, or placebo, once per week. Placebo capsules were compounded to look 162 similar and were taken orally (Belmar Pharma Solutions (Golden, CO, USA)). Study participants 163 were prescribed the drug for 48 weeks upon enrollment in the study and were dispensed 164 supplies for 12 weeks at a time.

165

166 Assessments

167 All assessments were performed at baseline, after 24 weeks, and after 48 weeks of 168 rapamycin treatment. Blood testing was performed two additional times, at 2 weeks and 4 169 weeks of treatment, to evaluate safety. All blood testing was performed by local Quest 170 Diagnostics of LabCorp laboratories, and included complete blood count (CBC), comprehensive 171 metabolic panel, liver function tests, renal function tests, and lipid panels. DEXA body 172 composition scans were performed primarily by DexaFit or Fitnescity locations, based on local 173 availability, though some participants utilized third party locations based on site availability. 174 Regardless of site, the outcome measures obtained by DEXA scans were body mass index (BMI). 175 visceral fat, bone mineral content, bone mineral density, and lean tissue mass. Gut health was 176 evaluated using the Thorne Gut Health test.

Summary health scores were calculated as a sum of responses on baseline survey
responses of health for questions of frequency of use of smoking, consuming caffeinated
beverages, consuming alcoholic beverages, eating sugary, salty, or "junk" foods, exercise
(vigorous and moderate intensity), and weight. Benefit Score was calculated by ranking the
percent change on each DEXA measure evenly into high, medium, and low benefit, and

summing scores into a meta score. VAT measures were reverse-scored, as decrease in VAT raw
values corresponds with improvement on this measure. The summary meta score was then
again divided evenly into a high, medium, and low ranking. High scores were considered
"improved", and low scores were considered "decline", while in-between scores were
considered "stasis".

187 Health-related QoL was assessed by the short-form 36 (SF-36) survey, which consists of 188 36 questions covering eight health domains: physical functioning, role limitations due to 189 physical health, bodily pain, general health perceptions, vitality (energy levels), social 190 functioning, role limitations due to emotional problems, and emotional health [44]. The 191 responses are scored and summarized to provide a profile of an individual's perceived health 192 status. Pain, fitness, and functional limitations were assessed using the Western Ontario and 193 McMaster Universities Osteoarthritis (WOMAC) index, which is a questionnaire that is 194 commonly used to assess the health status of individuals with osteoarthritis of the hip and knee 195 [45]. It consists of 24 items divided into three subscales: pain, stiffness, and physical function. 196 The responses are scored to provide quantitative assessments of the severity of symptoms and 197 functional limitations associated with osteoarthritis.

198

199 Adverse Events

Adverse events (AEs) were obtained through weekly monitoring forms sent out to participants. Clinical trial staff reviewed and documented AEs. Both expected (already known) and unexpected AEs were reported and documented. A full list is presented in **Table 2**.

203

204 Statistical analyses

All initial analyses were performed by researchers blinded to the study treatment. Demographic and baseline characteristics were summarized using descriptive statistics. All data were tested for normality using visual inspection of histograms and Q-Q plots, and Shapiro-Wilks tests were performed. Data were summarized using mean and standard deviation (SD) and where appropriate, counts and percentages were reported. Baseline data were compared between the three treatment arms using Analysis of Variance (ANOVA), independent t-test or

211 χ^2 test. To compare the difference in mean change from baseline to most recent follow-up (48) 212 weeks) between treatment arms, we employed ANOVA and BMI-adjusted marginal mixed-213 effect models. Following this, full age-, sex-, and BMI-adjusted linear mixed-effects models with 214 a repeated measures structure were conducted. Interaction terms (time by treatment arm, as 215 well as time by treatment arm by sex) were included to investigate group and gender effects 216 and their trajectory over time. Where appropriate, stratified post-hoc analyses were conducted 217 within sex and between treatment arms (10 mg vs. placebo and 5 mg vs. placebo). All analyses 218 were conducted using SPSS 28 (IBM, Armonk, NY, USA) and Python 3.10 (Python Software 219 Foundation). A p-value of p<0.05 was considered significant.

- 220
- 221 Results
- 222

223 Participant demographics

A total of 115 participants were included in this study, of whom 40 received 5 mg/week of rapamycin, 36 received 10 mg/week of rapamycin, and 39 received placebo (**Supplementary Fig S1a**). At baseline, all participant groups were comparable across measures of age, sex, height, weight, BMI, and blood safety markers, with the exception of the mean HbA1C, which was lower in the 5 mg group than placebo (5mg mean = 5.2%, SD = 0.2; placebo mean = 5.3%, SD = 0.3; t(72)=2.556, p=0.013; **Table 1**). Overall, participants were in exceptionally good health at baseline, as evaluated by self-reports of health (**Supplementary Fig S1b**).

231

232 Safety: Adverse events

AEs were collected throughout the study as reported by participants on periodic surveys or through direct contact with investigators (**Supplementary Fig 2a**; see **Table 2** for all AEs). The most commonly reported AEs were cold/flu/sinus symptoms, musculoskeletal pain, mouth sores, and malaise, with a greater number of AEs reported in the placebo group relative to treatment conditions (**Supplementary Fig 2b, Table 2**). The most commonly reported rapamycin specific AEs were gastrointestinal issues. Surprisingly, mouth sores, which are often associated with rapamycin treatment [46], were most frequently reported in the placebo group (placebo: n=27, 5 mg: n=4, 10 mg: n=14; **Table 2**), though the same number of individuals
reported mouth sores in the 10 mg and placebo group (n = 6).

242 Notably, throughout the length of the trial, participants in the rapamycin treatment 243 groups reported increased instances of improvements in chronic ailments (chronic issue flare) 244 that were present when they first entered the trial compared to placebo (placebo: n = 14, 5 mg: 245 n = 24, 10 mg: n = 28). Conversely, participants in the placebo group reported increased 246 instances of worsening of their chronic ailments (chronic issue severity) compared to treatment 247 groups (placebo: n = 12, 5 mg: n = 4, 10 mg: n = 6; **Table 2**). No significant safety-related issues 248 were detected in the blood work results of any participants during periodic check-ins, or after 249 the 48 week study period for the 105 participants who completed the entirety of the study 250 (Supplementary Table S1).

251 Of the 123 total participants enrolled in the study, Serious AEs (SAEs) were reported for 252 four rapamycin users (three in 5mg group and one in 10mg group) and two placebo users. 253 Specifically, in the 5 mg group, one participant was hospitalized during the study period due to 254 respiratory symptoms that seemed related to anemia, which resolved with a blood transfusion. 255 A second participant in the 5 mg group had a severe infection requiring treatment from their 256 healthcare provider, which resolved after medication use (prednisone, doxycycline, and 257 albuterol). The third participant in the 5mg group had a hamstring tear prior to the study, that 258 healed slowly during the trial. In the 10mg group, a participant reported a sore throat, but 259 tested positive for group A strep and was prescribed amoxicillin, which resolved the symptoms. 260 One participant in the placebo group died of myocardial infarction during the study period. A 261 second participant in the placebo group reported a stomach virus that required attention from 262 a medical provider, and was diagnosed with small urinary infection. Symptoms resolved after 263 treatment.

While not an intended endpoint for this study, the study period was during the COVID-19 pandemic, and a confirmed COVID-19 infection was reported for 25 participants: 10 in the placebo group (29%), 8 in the 5 mg treatment group (21%), and 7 in the 10 mg treatment group (21%). Among these, no differences in infection rates, symptom severity, duration of illness, or

length of recovery were noted between groups. Importantly, those with SAEs (described above)
were not noted to have COVID-19 upon physician testing.

270

271 Efficacy of rapamycin on healthspan metrics

272 DEXA Scan results

273 Participants underwent DEXA scans to assess visceral adipose tissue (VAT) mass, bone 274 mineral content (BMC), and lean tissue mass (LTM) at three timepoints (baseline, 24, and 48 275 weeks of treatment) to explore the effects of rapamycin on measures crucial for healthy aging 276 and the prevention of frailty and disease. At baseline, VAT mass, BMC, and LTM were similar 277 between the three treatment groups (Supplementary Table S2). Over the study period, VAT 278 mass increased most in the placebo group (mean = +35.34 g, SD = 290.76 g) and decreased in 279 the group taking 5 mg rapamycin (mean = -39.85 g, SD = 185.18 g), while BMC and LTM 280 increased only in the 10 mg rapamycin treatment group (BMC: mean = +19.41 g, SD = 104.34; 281 LTM = 517.87 g, SD = 2440.18). While notable trends of change in body composition measures 282 from baseline to 48 weeks were observed between treatment groups, none were statistically 283 significant (linear mixed-effects models interaction: VAT: F(2, 101.408) = 0.978, 284 p=0.379; BMC: F(2,104.415) = 1.403, p=0.250; LTM: F(2,126.996) = 1.115, p=0.331; BMD: 285 F(2,166.294) = 1.596, p=0.552) (Figure 1a, Supplementary Table S2). While some changes to 286 some body composition metrics (e.g. visceral adipose) in rapamycin treatment groups were 287 observed at 24 weeks, these effects stabilized to measures reported for 48 weeks by the end of 288 the trial (Supplementary Fig S3a, Supplementary Table S2). 289 As rapamycin has been suggested to have differential effects in males and females, we

explored this possibility by evaluating changes in DEXA scan data across sex (**Table 3**). Analysis with linear mixed-effects models revealed statistically significant differences in BMC change between groups across sex (interaction F(2, 193.245) = 4.489, p = 0.012, **Table 3**), which subsequent analysis revealed was specifically driven by improvements in the male 10 mg rapamycin treatment group vs placebo (interaction F(1, 129.224) = 4.563, p = 0.035, (**Figure 1b**). This was consistent with changes of bone mineral density (interaction F(1, 131.924) = 4.956, p = .028).

297 Similarly, statistically significant differences in LTM were observed between groups 298 when assessed across sex (F(2, 206.447) = 5.439, p = 0.005, **Table 3**), which subsequent 299 analyses revealed were primarily driven by differences between sex in the 10mg rapamycin treatment group (F(1, 134.554) = 8.880, p = 0.003, Figure 1c). Post-hoc within sex analyses 300 301 confirmed that gains in LTM over 48 weeks were distinct to female participants taking 10 mg 302 rapamycin compared to placebo (female 10mg = +1,939.7g (SD = 1,998.9) versus female 303 placebo = -298.1g (SD = 1,191.1); F(2, 41.242) = 6.423; $\beta = 55.5$, SE = 16.9, p = 0.002). This 304 highlights that the average improvement in LTM in female participants was particularly robust 305 at an estimated rate of 55.5g per week faster than those on placebo. No significant changes in 306 BMC and LTM were observed in all other groups, nor were any significant changes in VAT 307 observed upon subsequent analyses (Supplementary Fig S3b).

308 Notably, marked variability in measures of VAT, LMT, and BMC was observed for all 309 rapamycin users independent of dose (Table 3, Supplementary Table S2). This resulted in 310 dramatically different impacts for the highest and lowest responding individuals across all 311 measures for both males and females (Supplementary Figure S4). Exploration of raw values of 312 response for individual participants revealed categories of individuals with improvement and 313 decline for each body composition measure (Supplementary Table S2, Figure 2a). Comparing 314 across groups, we observed that a greater percentage of individuals in the improvement group 315 were rapamycin users, with no specific bias in response across all measures by sex (Figure 2b, 316 c). Upon further investigation of individual body composition measures, sex-agnostic rapamycin 317 associated improvement held true for VAT (Figure 2d), however, the percent of participants 318 showing improvement in BMC and LTM differed by gender (Figure 2e, f). This is particularly 319 notable for BMC, where two thirds of 10mg males showed improvement (Figure 2e), and in 320 LTM, where all of the 10mg female participants demonstrated improvements (Figure 2f). Upon 321 further investigation, we noted that improvements in VAT correlated with 322 improvements on BMC and LTM, as well as with improved weight and BMI (Figure 3a). 323 Given these findings, we computed a "Benefit Score" for users based on summary

324 scores of improvement or decline on each body composition measure evaluated by DEXA.

Benefit score was significantly associated with rapamycin use (t(44.41) = 2.175, p = 0.035),

326 though some placebo users also saw global improvements and subsequently high Benefit 327 Scores (Figure 3b). As our bioavailability study has previously suggested a 3.5x reduction in 328 potency for compounded rapamycin relative to generic, we reasoned that the 10mg group was 329 more likely to be in a relevant bioavailable therapeutic dose range, and thus further 330 investigated Benefit Score in the 10mg vs Placebo groups to explore what might be driving 331 differences in rapamycin response. Importantly, separation of Benefit Scores by rapamycin dose 332 and sex in this manner revealed a pronounced female benefit bias, with all female rapamycin 333 users showing only improvement on the Benefit Score (Figure 3c). Subsequent analysis of gut 334 health and blood biomarkers by benefit score revealed significant changes in measures of gut 335 dysbiosis (F(2,54) = 3.215, p = 0.04; t(54) = -2.150, p = 0.036), immune readiness (F(2, 54) = -2.150, p = 0.036), immune readiness (F(2, 54) = -2.150, p = -2.150, p336 3.157, p = 0.05; t(54) = 2.517, p = 0.015; Figure 3d), and LDL levels (F(2, 102) = 4.262, p = 0.017; 337 t(74) = -2.505, p = 0.014; Figure 3e) between high and low Benefit Scores, with rapamycin users 338 showing greater magnitude of beneficial change than placebo.

339

340 Blood Biomarkers

341 In addition to completing routine blood work for safety monitoring, blood biomarkers of 342 health, such as LDL, hemoglobinA1c, triglycerides, and insulin levels were collected throughout 343 the study. While there were no significant differences between groups in biomarkers that were 344 outside the healthy reference range after 48 weeks, significant differences between treatment 345 and control groups were observed for mean change in corpuscular hemoglobin (MCH: 5mg: -0.1 346 (0.9), 10mg: -0.4 (1.1), Placebo: 0.2 (1.2); F(2, 101) = 3.232, p = 0.040) and mean platelet 347 volume (MPV: 5mg: -0.1 (0.4), 10mg: -0.1 (0.4), Placebo: 0.1 (0.4); F(2, 101 = 4.802, p = 0.10). 348 Post-hoc testing between treatment group pairs revealed additional changes for participants in 349 the 10 mg rapamycin treatment group in chloride levels (10mg: +0.6 (1.5), Placebo: -0.3 (2.0); 350 t(65) = 2.125, p = 0.037), carbon dioxide levels (10mg: -1.2 (1.8), Placebo: -0.4 (2.2); t(65) =351 1.786, p = 0.079), and mean corpuscular volume (MCV: 10mg: -1.0 (2.2), Placebo: 0.4 (2.8); 352 t(65)=2.258, p = 0.027), and patients in the 5 mg rapamycin treatment group in platelets 353 (Supplementary Figure S5a-b, Supplementary Table S1). Stratifying by sex did not reveal any 354 additional patterns of significant change between dosing groups and controls over time.

355

356 Quality of life

357 Evaluation of rapamycin's effects on self-reported quality of life (QoL) was conducted 358 using the SF-36 scale. Baseline measures revealed generally high QoL scores across the study 359 cohort, with no notable significant differences between groups (overall QoL scores of 83.7 360 (10.4), 88.1 (7.0), and 84.5 (12.0) for the 5 mg, 10 mg, and placebo groups, respectively, (F(2, 361 110) = 1.987, p = 0.142; Supplementary Table S3). After 48 weeks of treatment most SF-36 362 scores improved in all groups, however, with the exception of general health (5mg: +5.6 (10.3), 363 10mg: +3.2 (10.0, Placebo: +0.8 (12.0); F(2, 87) = 4.488, p = 0.014), no statistically significant 364 changes were detected using marginal linear mixed-effect models between treatment groups 365 across time (Supplementary Figure S6a, Supplementary Table S3).

366 As we observed sex-specific differences in DEXA measures, we similarly evaluated 367 whether QoL measures differed across sex between the treatment groups over time (mean QoL 368 scores stratified by sex are presented in **Table 4**). Linear mixed-effect models were employed to 369 further explore the interaction of sex and treatment groups with change in QoL over time. 370 Significant longitudinal differences in pain between groups and sex were observed (interaction 371 F(2, 201.308) = 6.815, p = 0.001, which was driven by a sex difference specifically in the 10 mg 372 rapamycin treatment group (10mg vs Placebo: F(1, 130.926) = 16.403, p < 0.001, Figure 4a,b). 373 This was confirmed in post-hoc analysis, where specifically females taking 10 mg rapamycin 374 (+14.7 SD = 13.9) saw improvements in pain compared to placebo (β = 0.332, SE = 0.110, F(1, 375 (6.928) = 9.121, p = 0.020), indicating that similar to gains in LTM, among females, 376 improvements in pain are another robust effect of 48 weeks of rapamycin treatment. 377 Within the 10 mg rapamycin treatment group, the rate of improvement in social 378 functioning and overall quality of life also showed group and sex differences (Supplementary 379 **Table S3**), with both social functioning (+12.5 SD = 24.1) and QoL (+5.8 SD = 4.6) improving

380 most in the 10mg female group (group by sex interaction F(2, 188.862) = 2.701, p = 0.070 and

381 F(2, 200.291) = 2.028, p = 0.134, respectively). When limiting analyses to 10mg compared to the

382 placebo group, differences in the rate of improvements in social functioning and quality of life

383 between group and sex reached significance (interaction F(1, 132.742) = 5.551, p = 0.020 and

F(1, 123.268) = 6.753, p = 0.010, respectively), which, as with pain, appeared to be specifically
driven by females within the 10 mg rapamycin treatment group (Figure 4a,b).

386

387 Frailty

388 Finally, we measured symptoms of osteoarthritis (OA) using the WOMAC survey as a 389 marker for frailty, another important factor defining the length of an individual's healthspan. 390 Baseline scores were not significantly different across groups (Supplementary Table S3), and 391 linear mixed-effects models again revealed no significant patterns of change in scores across all 392 groups over the 48-week study period (Supplementary Figure S6b). However, given previous 393 sex-specific effects in other outcome measures, analyses of WOMAC scores were repeated by 394 exploring differences across sex and groups (**Table 4**). This revealed statistically significant 395 differences in the WOMAC pain score between groups and sex (interaction F(2, 194.531) =396 3.516, p=0.032), with improvements observed particularly for female participants in the 5 mg 397 and 10 mg rapamycin group (-0.9 SD = 1.8; -0.8 SD = 2.9, respectively; Figure 4c,d), and trends 398 of improvement for the overall frailty score in the same groups (**Supplementary Table S3**; 399 group by sex interaction F(2, 202.257) = 2.172, p = .117). Evaluation of changes across sex 400 limited to the 10 mg rapamycin group versus placebo revealed a significant improvement in 401 both measures (interaction F(1, 120.251) = 5.791, p = 0.018 and F(1, 111.480) = 5.925, p = 0.018402 0.017, respectively). This highlights that once again, female participants in the 10 mg group 403 appear to improve most (Figure 4c,d). No other significant differences were observed for this 404 measure.

405

406 Discussion

Few clinical trials to date have evaluated the effects of rapamycin and its derivatives in generally healthy individuals, and those that have been conducted are often challenged by a small cohort size, short-term follow-up, or both. While the most robust of these studies have suggested improvements in age-related immune decline in healthy elderly individuals administered low-dose everolimus for 6 to 16 weeks [41], no study to date has definitively demonstrated the efficacy of rapamycin for supporting healthy aging in normative aging

individuals. The PEARL trial represents one of the most robust and comprehensive efforts
evaluating the long-term safety and efficacy of low-dose rapamycin for addressing multiple
aspects of age-related decline in a normative aging cohort.

416 In the current study, no significant differences in markers of metabolic health, liver, and 417 kidney function, or moderate to severe AEs in the rapamycin treatment groups were reported 418 compared to placebo after 48 weeks. This is consistent with previous reports summarized in a 419 review by Maier's group that healthy individuals are not likely to experience serious side effects 420 from low dose rapamycin, and suggests that concerns over negative effects of rapamycin 421 stemming from studies of high-dose, daily usage in chronically ill individuals may have limited 422 applicability in the context of rapamycin use for healthy aging [47]. Indeed, we observed more 423 instances of individuals reporting improvements in chronic ailments in the rapamycin treatment 424 groups than in placebo, and more instances reported of worsening ailments in the placebo 425 group compared to treatment groups after 48 weeks. This effect will be important to 426 investigate further in longitudinal follow-up with PEARL participants.

427 While among PEARL participants, those taking 10 mg of rapamycin per week did initially 428 report more gastrointestinal and neurological AEs (e.g. diarrhea and headaches) compared to 429 those taking placebo, all (except for one) were acute AEs that resolved on their own, or were 430 not severe enough to prevent continuation of the rapamycin regimen. Interestingly, despite 431 well-known impacts of rapamycin on causing mouth sores and a strong association with its 432 bioavailability and potency [46, 48], participants in the placebo group reported increased 433 incidents of mouth sores than those in either of the treatment groups, despite the same 434 number of individuals reporting mouth sores in the 10 mg rapamycin group and placebo (n = 6). 435 This may be a unique property of compounded rapamycin, though follow-up studies are 436 currently underway to understand this more comprehensively.

Of note, the PEARL trial was ongoing during the COVID-19 pandemic and rapamycin has
been associated with favorable outcomes in response to SARS-CoV2 [8, 49, 50]. Consistent with
this, we did observe a decreased incidence of COVID-19 reports in the rapamycin treatment
groups (19.7%) compared to placebo (25.6%). Clinical trials are underway that are specifically

designed to more robustly evaluate the efficacy of rapamycin and its derivatives on COVIDoutcomes [28-32, 51].

443 Over the 48 weeks of the study, weekly rapamycin use demonstrated dose-dependent 444 and sex-specific improvements in multiple functional healthspan metrics compared to placebo, 445 including lean tissue mass, bone mineral content, pain (SF-36, WOMAC), social functioning (SF-446 36), overall guality of life (SF-36), and overall osteoarthritis (WOMAC) score. All statistically 447 significant benefits were observed in participants taking 10 mg rapamycin per week and 448 consistent with preclinical reports of a female-benefit bias in mice, female participants 449 demonstrated significant benefits across all the outcome measures except bone mineral 450 content [14, 18]. Notably, the most robust improvements observed after 48 weeks were 451 increases in lean muscle mass within this group. However, as all groups of rapamycin users 452 (across gender and dose) had individuals that showed large improvements in body composition 453 measures over time, a summary improvement score accounting for improvement or decline 454 across all DEXA body composition measures was computed as a Benefit Score. Importantly, all 455 women taking 10mg of rapamycin had improvements on the Benefit Score, and showed no 456 declines, whereas men were represented in both groups. Across all participants, those with 457 high benefit scores had significant improvements in gut health measures of gut dysbiosis and 458 immune readiness, and in LDL levels relative to those with low benefit scores. Greater 459 responses on these measures were observed for rapamycin users than placebo users. Taken 460 together, these findings suggest that digestive health, diet, and/or microbiome may play a 461 significant role in rapamycin response and subsequent likelihood of benefits, and will be a focus 462 of our future work.

Findings from this study that male participants in the 10 mg rapamycin group gained an average of 1.4% BMC over 48 weeks and female participants in the 10 mg group gained an average LTM of 4.5% hold significant promise for rapamycin in reducing risks of age-related disease and mortality. This is particularly true for the highest rapamycin responding individuals, who exhibit greater improvements in body composition than typical for individuals of this trial age cohort. For example, one female participant in the 10 mg rapamycin group exhibited a 19% improvement in lean muscle mass over the 48 week period, and another saw a 15% increase in

470 BMC over two years of taking rapamycin consistently during and post-trial. Given the expected 471 worsening of body composition metrics each year after the age of 60, which have a 472 compounding influence on the risk of age-related adverse outcomes, rapamycin clearly has an 473 important role as a gerotherapeutic in the future of healthy longevity medicine 474 While this trial extended notably longer than other human trials of rapamycin use for 475 healthy longevity to date, it is likely that even greater effects would be observed with an 476 increased observation period, a broader (specifically higher) range of doses, as well as a larger 477 study cohort. Further, while it was outside the scope of this study to determine all sources of 478 variability, there are several lifestyle factors (such as diet, alcohol consumption, sleep quality, 479 and activity levels) that may influence VAT, LTM, and BMC changes over time [52, 53], and 480 which may have yet-to-be-identified impacts on rapamycin bioavailability that would add value 481 to future studies on this topic.

482 Across all measures in this study, a remarkable level of variability in response was 483 observed for all rapamycin users, regardless of dose. Given our recent work on the variability of 484 rapamycin bioavailability in individuals, we expect that it played a meaningful role in the results 485 observed here, though this trial concluded prior to our findings on bioavailability. Further, we 486 have discovered since the conclusion of this trial that compounded rapamycin is approximately 487 3.5x less bioavailable than commercially available formulations, suggesting that the 5mg and 488 10mg rapamycin groups received an average equivalent of 1.4mg and 2.9mg respectively [48]. 489 Although both doses are relatively low, making the observation of benefits in the treatment 490 group more striking, the 10mg rapamycin cohort in this study was more firmly in the range of 491 what is thought to be an optimal longevity dose range for rapamycin [8, 41, 47, 54]. While 492 future studies will be necessary to draw clear conclusions on whether even higher doses lead to 493 improved effects, we expect that this is a key factor in the often stronger and more reliable 494 patterns of improvement seen for the 10mg rapamycin cohort relative to the 5mg cohort. We 495 highlight this to emphasize the importance of personalized rapamycin dosing and continual 496 routine monitoring of blood rapamycin levels in users to ensure maximal benefits, until such 497 time as the optimal longevity dosing dynamics for rapamycin are more clearly understood.

498 Beyond physical measures of rapamycin impacts explored in this study, self-reported 499 measures of perceived health and quality of life also showed improvement for all groups. This is 500 especially important in a normative aging population, still in their healthspan, as evaluating 501 changes in QoL captures multiple dimensions of health and functioning that both precede and 502 go beyond disease progression alone. As maintaining an active, pain-free, high quality of life 503 (QoL) in aging is one of the most important aspects of healthspan, findings from the current 504 study that rapamycin users had improved scores on multiple measures of the well-established 505 SF-36 and WOMAC scales are particularly promising. While a female-benefit bias was noted for 506 both measures, significant improvements were observed only for the female 10mg rapamycin 507 group. This is consistent with previous findings in a cohort of 333 adults using off-label 508 rapamycin for healthy aging in which rapamycin was associated with increased reports of 509 happiness, brain function, feelings of youthfulness, calm, reduced anxiety and pain compared 510 to non-users in that same timeframe (up to 10 years for some participants) [8].

511 Of particular note, with PEARL, we are the first to show that 10 mg rapamycin/week for 512 48 weeks has a modest but significant benefit on osteoarthritis symptoms, specifically in 513 women, based on the WOMAC clinical OA assessment. As our study was within a normative 514 aging population, small improvements in early age-related progression of OA could lead to 515 substantial cumulative benefits over time on frailty outcomes [55, 56]. Despite this, follow-up 516 studies are required to determine why males did not demonstrate similar OA associated 517 benefits in this study, and what additional adjustments or considerations would be required for 518 men to derive similar OA related benefits.

519

520 Conclusion

521 The PEARL trial is the largest and longest decentralized RCT evaluating the safety and efficacy of 522 low, intermittent "longevity doses" of rapamycin on healthy aging through the measurement of 523 clinically relevant healthspan metrics. Our findings provide evidence that low dose, intermittent 524 rapamycin regimens are well tolerated and do not lead to any serious adverse events or clinical 525 abnormalities when administered for at least one year within normative aging individuals. 526 Beyond this, we observed benefits for rapamycin users in the PEARL trial, as measured by

significant improvements in lean muscle mass, pain, social functioning, frailty outcomes, and
overall quality of life in females, and improved bone mineral density in males. Further, there
were some individuals in the rapamycin treatment groups that experienced large
improvements in body composition metrics after 48 weeks, which were further associated with
beneficial changes in gut health and LDL levels. Future work will more comprehensively explore
what drives high response rates to rapamycin, and will aim to identify biometric signatures that
can be used to predict clinical effectiveness and inform personalized treatment strategies.

534 As our previous investigation on the bioavailability of rapamycin suggests no significant 535 differences between men and women, further investigation in to mediators of sex specific 536 effects of rapamycin are warranted to elucidate what role factors such as differences in hormone signaling, growth factor signaling, mTOR signaling activity, genetic polymorphisms, or 537 538 other factors meaningfully contribute to the sex-specific effects we observed in this study, and 539 particularly the female-benefit bias we observed for most measures. While the current report 540 details the primary endpoints for the PEARL trial, many PEARL participants continue to take 541 longevity doses of rapamycin, and have consented to share ongoing information. Reports on 542 these longitudinal studies will be released publicly as available, in keeping with our strong 543 conviction that freely permitting combinatory result analyses will allow for better 544 understanding of optimal dosing, safety, changes in aging biomarkers, and overlapping 545 outcomes for this important gerotherapeutic intervention.

546 Collectively, the PEARL clinical trial is one of the first to provide evidence that low-dose 547 rapamycin may be safely administered for extended periods of time and may counteract 548 several aspects of age-related decline. Further, it represents the first study indicating dose-549 dependent, sex specific efficacy for rapamycin in improving healthspan metrics in humans. As 550 such, our collective evidence suggests that well beyond merely clinical measures of health 551 improvements, rapamycin may promote essential, comprehensive well-being associated with 552 "adding life to years, not just years to life".

- 553
- 554
- 555

556 Statements and Declarations:

557

558 Acknowledgements

- 559 The authors would like to thank the participants who took part in this study. Financial support
- 560 from our generous donors, particularly Vitalik Buterin, Micah Zoltu, Brad Armstrong, and
- anonymous gifts, administrative support, and article publishing charges were provided by
- 562 AgelessRx. Clinical trial oversight was conducted by PHAGE corporation. We extend special
- thanks to Mikhail Blagosklonny, James Watson, Alan Green and Thorne for their participation
- and support in conducting this trial.
- 565

566 *Competing interests*

- 567 GH, VL, AN, MM, SM, AI, and SZ are employees and shareholders of AgelessRx. JH has received 568 financial compensation from AgelessRx for their contributions.
- 569

570 Author contributions

- 571 Virginia Lee, Andy Nyquist, Anar Isman, and Sajad Zalzala designed and implemented the study.
- 572 Girish Harinath, Jesper Hagemeier, and Stefanie Morgan performed data analysis. Girish
- 573 Harinath, Virginia Lee, Andy Nyquist, Mauricio Moel, Stefanie Morgan, Anar Isman, and Sajad
- 574 Zalzala wrote and edited the manuscript. All work was supervised by Stefanie Morgan, Anar
- 575 Isman, and Sajad Zalzala. Corresponding author is Stefanie Morgan.
- 576

577 References

- 578 1. Al-Maskari F. LIFESTYLE DISEASES: An Economic Burden on the Health Services. UN
- 579 Chronicle [Internet]. [cited 2024 August]. Available from:
- 580 https://www.un.org/en/chronicle/article/lifestyle-diseases-economic-burden-health-
- 581 <u>services#:~:text=By%202030%2C%20the%20proportion%20of,African%20and%20Eastern%20M</u>
- 582 <u>editerranean%20regions</u>.
- 583 2. Ford ES, Bergmann Mm Fau Kröger J, Kröger J Fau Schienkiewitz A, Schienkiewitz A
- 584 Fau Weikert C, Weikert C Fau Boeing H, Boeing H. Healthy living is the best revenge: findings

- 585 from the European Prospective Investigation Into Cancer and Nutrition-Potsdam study. (1538-
- 586 3679 (Electronic))
- 587 3. Kvaavik E, Batty Gd Fau Ursin G, Ursin G Fau Huxley R, Huxley R Fau Gale CR, Gale
- 588 CR. Influence of individual and combined health behaviors on total and cause-specific mortality
- in men and women: the United Kingdom health and lifestyle survey. (1538-3679 (Electronic))
- 590 4. Coe E, Dewhurst M, Hartenstein L, Hextall A, Latkovic T. At least six years of higher
- quality life for everyone is within reach. Adding years to life and life to years [Internet]. 2022
- 592 [cited 2024 August]. Available from: <u>https://www.mckinsey.com/mhi/our-insights/adding-</u>
 593 years-to-life-and-life-to-years.
- 594 5. Garmany A, Yamada S, Terzic A. Longevity leap: mind the healthspan gap. NPJ Regen
- 595 Med. 2021;6(1):57 https://doi.org/10.1038/s41536-021-00169-5.
- 596 6. Sierra F. The Emergence of Geroscience as an Interdisciplinary Approach to the
- 597 Enhancement of Health Span and Life Span. (2157-1422 (Electronic))
- 598 7. Kulkarni AS, Aleksic S, Berger DM, Sierra F, Kuchel GA, Barzilai N. Geroscience-guided
- repurposing of FDA-approved drugs to target aging: a proposed process and prioritization.
- 600 Aging Cell. 2022;21(4):e13596 <u>https://doi.org/10.1111/acel.13596</u>.
- Kaeberlein TL, Green AS, Haddad G, Hudson J, Isman A, Nyquist A, et al. Evaluation of
 off-label rapamycin use to promote healthspan in 333 adults. Geroscience. 2023;45(5):2757-68
 https://doi.org/10.1007/s11357-023-00818-1.
- 604 9. Mannick JB, Lamming DW. Targeting the biology of aging with mTOR inhibitors. Nat 605 Aging. 2023;3(6):642-60 https://doi.org/10.1038/s43587-023-00416-y.
- 606 10. Chung J, Kuo Cj Fau Crabtree GR, Crabtree Gr Fau Blenis J, Blenis J. Rapamycin-FKBP
- 607 specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein
- 608 kinases. (0092-8674 (Print))
- 609 11. Castilho RM, Squarize Ch Fau Chodosh LA, Chodosh La Fau Williams BO, Williams Bo
- 610 Fau Gutkind JS, Gutkind JS. mTOR mediates Wnt-induced epidermal stem cell exhaustion and
- 611 aging. (1875-9777 (Electronic))

612 12. Urfer SR, Kaeberlein TL, Mailheau S, Bergman PJ, Creevy KE, Promislow DEL, et al. A

613 randomized controlled trial to establish effects of short-term rapamycin treatment in 24

614 middle-aged companion dogs. GeroScience. 2017;39(2):117-27 10.1007/s11357-017-9972-z.

615 13. Robida-Stubbs S, Glover-Cutter K Fau - Lamming DW, Lamming Dw Fau - Mizunuma M,

616 Mizunuma M Fau - Narasimhan SD, Narasimhan Sd Fau - Neumann-Haefelin E, Neumann-

617 Haefelin E Fau - Sabatini DM, et al. TOR signaling and rapamycin influence longevity by

618 regulating SKN-1/Nrf and DAF-16/FoxO. (1932-7420 (Electronic))

619 14. Miller RA, Harrison De Fau - Astle CM, Astle Cm Fau - Fernandez E, Fernandez E Fau -

620 Flurkey K, Flurkey K Fau - Han M, Han M Fau - Javors MA, et al. Rapamycin-mediated lifespan

621 increase in mice is dose and sex dependent and metabolically distinct from dietary restriction.

622 (1474-9726 (Electronic))

623 15. Juricic P, Lu Y-X, Leech T, Drews LF, Paulitz J, Lu J, et al. Long-lasting geroprotection from

brief rapamycin treatment in early adulthood by persistently increased intestinal autophagy.

625 Nature Aging. 2022;2(9):824-36 10.1038/s43587-022-00278-w.

Bitto A, Ito TK, Pineda VV, LeTexier NJ, Huang HZ, Sutlief E, et al. Transient rapamycin
treatment can increase lifespan and healthspan in middle-aged mice. eLife. 2016;5:e16351
10.7554/eLife.16351.

629 17. Barnett BG, Wesselowski SR, Gordon SG, Saunders AB, Promislow DEL, Schwartz SM, et

al. A masked, placebo-controlled, randomized clinical trial evaluating safety and the effect on

631 cardiac function of low-dose rapamycin in 17 healthy client-owned dogs. (2297-1769 (Print))

632 18. Arriola Apelo SI, Pumper CP, Baar EL, Cummings NE, Lamming DW. Intermittent

633 Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice. (1758-535X

634 (Electronic))

635 19. Powers RW, 3rd, Kaeberlein M Fau - Caldwell SD, Caldwell Sd Fau - Kennedy BK,

Kennedy Bk Fau - Fields S, Fields S. Extension of chronological life span in yeast by decreased
TOR pathway signaling. (0890-9369 (Print))

638 20. Colman RJ, Anderson Rm Fau - Johnson SC, Johnson Sc Fau - Kastman EK, Kastman Ek

639 Fau - Kosmatka KJ, Kosmatka Kj Fau - Beasley TM, Beasley Tm Fau - Allison DB, et al. Caloric

640 restriction delays disease onset and mortality in rhesus monkeys. (1095-9203 (Electronic))

641 21. Harrison DE, Strong R Fau - Sharp ZD, Sharp Zd Fau - Nelson JF, Nelson Jf Fau - Astle CM,

- Astle Cm Fau Flurkey K, Flurkey K Fau Nadon NL, et al. Rapamycin fed late in life extends
- 643 lifespan in genetically heterogeneous mice. (1476-4687 (Electronic))
- 644 22. Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, et al. Rapamycin, But Not
- 645 Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous Mice. The Journals
- of Gerontology: Series A. 2011;66A(2):191-201 10.1093/gerona/glq178.
- 647 23. Flynn JM, O'Leary Mn Fau Zambataro CA, Zambataro Ca Fau Academia EC, Academia
- 648 Ec Fau Presley MP, Presley Mp Fau Garrett BJ, Garrett Bj Fau Zykovich A, et al. Late-life
- 649 rapamycin treatment reverses age-related heart dysfunction. (1474-9726 (Electronic))
- 650 24. Selvarani R, Mohammed S, Richardson A. Effect of rapamycin on aging and age-related
- diseases-past and future. Geroscience. 2021;43(3):1135-58 <u>https://doi.org/10.1007/s11357-</u>
- 652 <u>020-00274-1</u>.
- 25. Zhang Y, Zhang J, Wang S. The role of rapamycin in healthspan extension via the delay of
- 654 organ aging. Ageing Res Rev. 2021;70:101376 <u>https://doi.org/10.1016/j.arr.2021.101376</u>.
- 655 26. RapAdmin. Breaking: 15% Healthy Lifespan improvement via Rapamycin seen in
- 656 Marmosets 2024 [Available from: <u>https://www.rapamycin.news/t/breaking-15-healthy-</u>
- 657 lifespan-improvement-via-rapamycin-seen-in-marmosets/14325.
- 658 27. Weston AD, Grossardt BR, Garner HW, Kline TL, Chamberlain AM, Allen AM, et al.
- 659 Abdominal body composition reference ranges and association with chronic conditions in an
- age- and sex-stratified representative sample of a geographically defined American population.
- J Gerontol A Biol Sci Med Sci. 2024;79(4) https://doi.org/10.1093/gerona/glae055.
- 662 28. Hunter GR, Gower BA, Kane BL. Age related shift in visceral fat. Int J Body Compos Res.
 663 2010;8(3):103-8
- Volpi E, Nazemi R, Fujita S. Muscle tissue changes with aging. Curr Opin Clin Nutr Metab
 Care. 2004;7(4):405-10 https://doi.org/10.1097/01.mco.0000134362.76653.b2.
- 666 30. Whitaker KM, Choh AC, Lee M, Towne B, Czerwinski SA, Demerath EW. Sex differences
- 667 in the rate of abdominal adipose accrual during adulthood: the Fels Longitudinal Study. Int J
- 668 Obes (Lond). 2016;40(8):1278-85 <u>https://doi.org/10.1038/ijo.2016.48</u>.

- 669 31. Berger C, Langsetmo L, Joseph L, Hanley DA, Davison KS, Josse R, et al. Change in bone
- 670 mineral density as a function of age in women and men and association with the use of
- 671 antiresorptive agents. CMAJ. 2008;178(13):1660-8 <u>https://doi.org/10.1503/cmaj.071416</u>.
- 672 32. Alswat KA. Gender disparities in osteoporosis. J Clin Med Res. 2017;9(5):382-7
- 673 <u>https://doi.org/10.14740/jocmr2970w</u>.
- 674 33. Mikkola TM, Kautiainen H, von Bonsdorff MB, Salonen MK, Wasenius N, Kajantie E, et al.
- Body composition and changes in health-related quality of life in older age: a 10-year follow-up
- of the Helsinki Birth Cohort Study. Qual Life Res. 2020;29(8):2039-50
- 677 <u>https://doi.org/10.1007/s11136-020-02453-1</u>.
- 678 34. Chlabicz M, Dubatowka M, Jamiolkowski J, Sowa P, Lapinska M, Raczkowski A, et al.
- 679 Subjective well-being in non-obese individuals depends strongly on body composition. Sci Rep.
- 680 2021;11(1):21797 <u>https://doi.org/10.1038/s41598-021-01205-6</u>.
- 681 35. Lin H, Salech F, Lim A, Vogrin S, Duque G. The effect of rapamycin and its analogues on
- age-related musculoskeletal diseases: a systematic review. Aging Clin Exp Res.
- 683 2022;34(10):2317-33 <u>https://doi.org/10.1007/s40520-022-02190-0</u>.
- 684 36. den Hartigh LJ, Goodspeed L, Wang SA, Kenerson HL, Omer M, O'Brien KD, et al. Chronic
- oral rapamycin decreases adiposity, hepatic triglycerides and insulin resistance in male mice fed
- a diet high in sucrose and saturated fat. Exp Physiol. 2018;103(11):1469-80
- 687 <u>https://doi.org/10.1113/EP087207</u>.
- 688 37. Konopka AR, Lamming DW, Investigators RP, Investigators E. Blazing a trail for the
- clinical use of rapamycin as a geroprotecTOR. Geroscience. 2023;45(5):2769-83
- 690 <u>https://doi.org/10.1007/s11357-023-00935-x</u>.
- 691 38. Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, et al. mTOR
- 692 inhibition improves immune function in the elderly. (1946-6242 (Electronic))
- 693 39. Mannick JB, Morris M, Hockey H-UP, Roma G, Beibel M, Kulmatycki K, et al. TORC1
- 694 inhibition enhances immune function and reduces infections in the elderly. Science
- Translational Medicine. 2018;10(449):eaaq1564 10.1126/scitranslmed.aaq1564.

- 696 40. Mannick JB, Teo G, Bernardo P, Quinn D, Russell K, Klickstein L, et al. Targeting the
- 697 biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b
- 698 and phase 3 randomised trials. (2666-7568 (Electronic))
- 699 41. Mannick JB, Morris M, Hockey HP, Roma G, Beibel M, Kulmatycki K, et al. TORC1
- inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med.
- 701 2018;10(449) https://doi.org/10.1126/scitranslmed.aaq1564.
- 702 42. Walters HE, Cox LS. mTORC inhibitors as broad-spectrum therapeutics for age-related
- 703 diseases. Int J Mol Sci. 2018;19(8) <u>https://doi.org/10.3390/ijms19082325</u>.
- 43. Viscomi MT, D'Amelio M, Cavallucci V, Latini L, Bisicchia E, Nazio F, et al. Stimulation of
- autophagy by rapamycin protects neurons from remote degeneration after acute focal brain
- 706 damage. Autophagy. 2012;8(2):222-35 10.4161/auto.8.2.18599.
- 707 44. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.
- 708 Conceptual framework and item selection. (0025-7079 (Print))
- 709 45. Riddle DL, Perera RA. The WOMAC pain scale and crosstalk from co-occurring pain sites
- 710 in people with knee pain: A causal modeling study. Phys Ther. 2020;100(10):1872-81
- 711 <u>https://doi.org/10.1093/ptj/pzaa098</u>.
- 712 46. Peterson DE, O'Shaughnessy JA, Rugo HS, Elad S, Schubert MM, Viet CT, et al. Oral
- 713 mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on
- pathobiology and impact on clinical practice. Cancer Med. 2016;5(8):1897-907
- 715 <u>https://doi.org/10.1002/cam4.761</u>.
- 716 47. Lee DJW, Hodzic Kuerec A, Maier AB. Targeting ageing with rapamycin and its
- 717 derivatives in humans: a systematic review. Lancet Healthy Longev. 2024;5(2):e152-e62
- 718 <u>https://doi.org/10.1016/S2666-7568(23)00258-1</u>.
- 719 48. Harinath G, Lee V, Nyquist A, Moel M, Wouters M, Hagemeier J, et al. The bioavailability
- of compounded and generic rapamycin in normative aging individuals: A retrospective study
- 721 and review with clinical implications. MedRxiv. 2024
- 722 <u>https://doi.org/10.1101/2024.08.12.24311432</u>.

- 723 49. Patocka J, Kuca K, Oleksak P, Nepovimova E, Valis M, Novotny M, et al. Rapamycin: Drug
- 724 Repurposing in SARS-CoV-2 Infection. Pharmaceuticals (Basel). 2021;14(3)

725 https://doi.org/10.3390/ph14030217.

- 726 50. Singla A, Harun N, Dilling DF, Merchant K, McMahan S, Ingledue R, et al. Safety and
- 727 efficacy of sirolimus in hospitalised patients with COVID-19 pneumonia. Respir Investig.
- 728 2024;62(2):216-22 https://doi.org/10.1016/j.resinv.2023.12.009.
- 51. Bischof E, Siow RC, Zhavoronkov A, Kaeberlein M. The potential of rapalogs to enhance
- resilience against SARS-CoV-2 infection and reduce the severity of COVID-19. Lancet Healthy
- 731 Longev. 2021;2(2):e105-e11 https://doi.org/10.1016/S2666-7568(20)30068-4.
- 732 52. Lv X, Cai J, Li X, Wang X, Ma H, Heianza Y, et al. Body composition, lifestyle, and
- depression: a prospective study in the UK biobank. BMC Public Health. 2024;24(1):393
- 734 https://doi.org/10.1186/s12889-024-17891-6.
- 735 53. United States. Public Health Service. Office of the Surgeon General. 6 Determinants of
- bone health. Bone health and osteoporosis : a report of the Surgeon General. Rockville, Md.:
- 737 U.S. Dept. of Health and Human Services, Public Health Service, Office of the Surgeon General;
- 738 2004. p. xxxii, 404 p.
- 739 54. Blagosklonny MV. Rapamycin for longevity: opinion article. Aging (Albany NY).
- 740 2019;11(19):8048-67 https://doi.org/10.18632/aging.102355.
- 741 55. Puts MT, Toubasi S, Atkinson E, Ayala AP, Andrew M, Ashe MC, et al. Interventions to
- 742 prevent or reduce the level of frailty in community-dwelling older adults: a protocol for a
- scoping review of the literature and international policies. BMJ Open. 2016;6(3):e010959
- 744 https://doi.org/10.1136/bmjopen-2015-010959.
- 745 56. Apostolo J, Cooke R, Bobrowicz-Campos E, Santana S, Marcucci M, Cano A, et al.
- 746 Effectiveness of interventions to prevent pre-frailty and frailty progression in older adults: a
- 747 systematic review. JBI Database System Rev Implement Rep. 2018;16(1):140-232
- 748 https://doi.org/10.11124/JBISRIR-2017-003382.
- 749
- 750
- 751

752 Figure Legends

Figure 1. Effects of rapamycin use on changes in measures of body composition. Notable
trends of change in body composition from baseline to 48 weeks were observed between
treatment groups for all subjects (a). Analysis of changes in body composition measures within
sex revealed that bone mineral content improved significantly for men taking 10mg rapamycin
(b) as did lean tissue mass for females taking 10mg rapamycin (c). *p <0.05, **p ≤ 0.005

Figure 2. Heterogeneity in rapamycin response reveals differential patterns of effects. Within
all study arms, individual participants showed marked improvement and decline for each
measure of body composition (a). A greater percentage of individuals in the improvement
group were rapamycin users (b), with no specific bias in response across all measures by sex (c).
Similar trends were observed for measures of VAT (d), however, BMC (e), and LTM (f) showed
sex-specific improvement and decline.

765

766 Figure 3. Rapamycin response categorized by Benefit Scores revealed biological change 767 differences by response type. Improvements in VAT correlated with improvements on BMC 768 and LTM, as well as with improved weight and BMI (a). A "Benefit Score" was computed for 769 users based on summary scores of improvement or decline on each body composition measure 770 evaluated by DEXA, which was significantly associated with rapamycin use (b). Separation of 771 Benefit Scores by rapamycin dose and sex revealed a pronounced female benefit bias, with only 772 improvement for all female rapamycin users (c). Subsequent analysis of gut health and blood 773 biomarkers by benefit score revealed significant changes in measures of gut dysbiosis, immune 774 readiness (d), and LDL levels (e) between high and low Benefit Scores, with greater magnitude 775 of beneficial change for rapamycin users than placebo.

776

Figure 4. Effects of rapamycin use on quality of life and frailty. Quality of life measures from
the SF-36 showed improvements across most measures for female rapamycin users (a), with
statistically significant improvements in scores of pain, social functioning, and overall quality of
life. Male rapamycin users showed only trends of improvement for many measures, particularly

for the 5mg cohort (b). Similar patterns were seen for frailty measures from the WOMAC scale,
with female rapamycin users showing improvements across most measures, and significant
improvements in pain and overall frailty (c). In contrast, male rapamycin users did not show
improvements on WOMAC scores relative to controls (d).

Supplementary Figure S1. PEARL trial design and participant health scores. Schematic of trial
 enrollment, participant screening, randomization, and followup (a), and a summary of all
 participants health scores (b) highlighting significant baseline health of participants in this
 study.

790

Supplementary Figure S2. Adverse events and types for PEARL participants. A summary of
adverse event types by trial arm showed no rapamycin-specific adverse event patterns (a).
Further investigation of adverse event types revealed similar effects for all trial arms, with the
exception of a higher proportion of gastrointestinal events reported for rapamycin users than
controls (b).

796

797 Supplementary Figure S3. Effects of rapamycin use on sex-specific changes in measures of

body composition over time. Change in body composition measures at the study midpoint (24
weeks) showed evidence of some measure of change (a) that largely stabilized to the patterns
reported after 48 weeks. Change at 48 weeks of VAT, and of BMC in females and LTM in males
did not show statistically significant improvements for rapamycin users relative to controls (b).

802

803 Supplementary Figure S4. Heterogeneity of rapamycin response in body composition

measures. Within trial arms, notable differences in participant responses were observed across
 all measures, with sex-specific differences in proportion of participants improving or declining
 for most measures.

807

808 **Supplementary Figure S5. Changes in blood biomarkers in response to rapamycin use.** While 809 no significant differences in biomarkers were outside the healthy reference range after 48

810	weeks, significant differences between treatment and control groups were observed for mean
811	change in corpuscular hemoglobin (MCH) and mean platelet volume (MPV), and for the 10 mg
812	rapamycin group in chloride levels, carbon dioxide levels, and mean corpuscular volume (MCV),
813	and patients in the 5 mg rapamycin treatment group in platelets (a). No statistically significant
814	changes were seen for other biomarkers (b).
815	
816	Supplementary Figure S6. Effects of rapamycin use on quality of life and frailty measures
817	across groups. After 48 weeks of treatment most SF-36 scores of perceived Quality of Life
818	improved in all groups (a), as did WOMAC scores of frailty (b).
819	
820	
821	
822	
823	
824	
825	
826	
827	
828	
829	
830	
831	
832	
833	
834	
835	
836	
837	
838	

839 Tables

Table 1: Baseline demographics and blood safety markers								
	5 mg	10 mg	Placebo	F(df1, df2)	p-value			
	N=40	N=36	N=39					
	Mean (SD)	Mean (SD)	Mean (SD)					
Age (years)	61.2 (7.6)	62.4 (9.1)	62.6 (6.6)	0.425(2, 112)	0.655			
Sex (Female) N (%)	17 (42.5)	9 (25.0)	15 (38.5)	χ ² =2.732(2)	0.255			
Height (cm)	171.9 (10.0)	176.2 (9.0)	175.0 (9.1)	1.940(2, 101)	0.149			
Weight (kg)	75.6 (15.3)	80.1 (13.6)	75.2 (14.5)	1.263(2, 105)	0.287			
BMI (kg/m ²)	25.2 (3.5)	25.6 (3.3)	24.3 (3.0)	1.407 (2, 100)	0.250			
Glucose (mg/dL)	90.9 (3.5)	92.1 (8.8)	91.5 (11.1)	0.160(2, 112)	0.852			
LDL cholesterol (mg/dL)	107.8 (34.4)	104.3 (39.5)	115.1 (32.4)	0.921(2, 112)	0.401			
Non-HDL cholesterol	119.4 (37.4)	121.6 (43.5)	134.2 (34.5)	1.683(2, 112)	0.191			
(mg/dL)								
Triglycerides (mg/dL)	86.2 (32.4)	90.0 (39.8)	92.8 (45.8)	0.280(2, 112)	0.756			
HbA1c (%)	5.2 (0.2)	5.3 (0.2)	5.3 (0.3)	3.418(2, 106)	0.036*			
Insulin (uIU/mL)	5.8 (5.2)	6.1 (4.2)	5.0 (3.2)	0.528(2, 110)	0.528			
ALT (U/L)	22.1 (10.8)	23.4 (9.0)	22.4 (12.9)	0.141(2, 112)	0.869			
AST (U/L)	22.7 (7.2)	23.4 (5.3)	22.6 (6.7)	0.154(2, 112)	0.857			
BUN (mg/dL)	16.8 (4.9)	15.8 (2.9)	16.3 (4.4)	0.487(2, 112)	0.616			
Creatinine (mg/dL)	0.9 (0.2)	1.0 (1.2)	1.0 (0.3)	1.045(2, 112)	0.355			
eGFR (mL/min/1.73m ²)	85.4 (14.1)	83.0 (10.8)	79.1 (15.3)	2.007(2, 108)	0.139			

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; BUN: blood urea nitrogen; eGFR: estimated glomerular filtration rate; HbA1c: hemoglobin A1c; HDL: high-density lipoprotein; LDL: low-density lipoprotein; SD: standard deviation.

Groups were compared using Analysis of Variance and post-hoc independent t-test. *p < 0.05.

ted adverse events during study period
ted adverse events during study period

	5 mg	10 mg	Placebo
Cardiovascular			
-Cardiological event	-	-	1 (2.6%) 1
-Discomfort/Tightness in chest	1 (2.5%) 1	-	-
Gastrointestinal			
-Lower gastrointestinal symptoms	4 (10%) 5	6 (16.7%) 9	3 (7.7%) 3
-Upper and lower gastrointestinal symptoms	3 (7.5%) 3	1 (2.8%) 2	1 (2.6%) 1
-Upper gastrointestinal symptoms	2 (5%) 5	3 (8.3%) 4	-
Musculoskeletal and Orthopedic			
-Musculoskeletal pain	10 (25%) 19	12 (33.3%) 20	11 (28.2%) 20
-Deep tissue injury (closed)	1 (2.5%) 2	-	1 (2.6%) 1
-Musculoskeletal/Orthopedic injury (closed)	1 (2.5%) 1	-	1 (2.6%) 1
Neurological			
-Altered spatial orientation	1 (2.5%) 1	3 (8.3%) 7	2 (5.1%) 3
-Cognitive decline	-	1 (2.8%) 1	-
-Neuromuscular symptoms	-	1 (2.8%) 1	2 (5.1%) 2
Oral and Dental			
-Mouth sores	3 (7.5%) 4	6 (16.7%) 14	6 (15.4%) 27
-Dental symptoms	2 (5%) 3	2 (5.6%) 2	1 (2.6%) 1
Respiratory			
-Cold/Flu/Sinus symptoms	23 (57.5%) 35	19 (52.8%) 29	22 (56.4%) 33
-Respiratory symptoms	1 (2.5%) 2	-	-
Sensory			
-Auditory perception symptoms	2 (5%) 2	3 (8.3%) 3	2 (5.1%) 2
-Visual perception symptoms	1 (2.5%) 1	1 (2.8%) 1	-
Skin and Wound			
-Superficial wound/Skin irritation	6 (15%) 8	7 (19.4%) 11	9 (23.1%) 12
-Deep wound (opened)	-	-	2 (5.1%) 2
-Skin bacterial/fungal infection	1 (2.5%) 1	-	2 (5.1%) 2
Urinary, Kidney, and Reproductive			
-Kidney/Urinary symptoms	4 (10%) 5	2 (5.6%) 2	2 (5.1%) 2

-Menopausal symptoms	1 (2.5%) 1	1 (2.8%) 1	2 (5.1%) 2
Other			
-Erectile dysfunction	-	1 (2.8%) 1	-
-Malaise	3 (7.5%) 11	2 (5.6%) 2	1 (2.6%) 1
-Eye infection/disorder	1 (2.5%) 1	1 (2.8%) 1	1 (2.6%) 1
-Mental Health Symptoms	1 (2.5%) 1	1 (2.8%) 1	1 (2.6%) 1
-Pain (not otherwise specified)	1 (2.5%) 1	1 (2.8%) 1	1 (2.6%) 1
-Sleep disturbances	-	1 (2.8%) 1	-
Chronic Issue Flare	12 (30%) 23	13 (36.1%) 28	10 (25.6%) 14
Chronic Issue Severity	4 (10%) 4	4 (11.1%) 6	4 (10.3%) 12

*Includes all reported events by the cohort. Some participants had multiple events or experienced the same events multiple times. Adverse events reported as: n participants (%) n events. Chronic issue flare: participants entered the PEARL trial with a chronic ailment which improved or stayed the same during the trial. Chronic issue severity: participants entered the PEARL trial with a chronic ailment that worsened during the trial.



s, Males			Changes by	/ sex	Changes by group	
5 mg	10 mg	Placebo	F(df1, df2)†	p-value†	F(df1, df2) ‡	p-value ‡
500.6	407.0	518.2	E(2, 27) – 0, 221	0 705		
(449.7)	(346.2)	(321.5)	1(2, 37) - 0.231	0.795	F(5, 107) =	< 0.001
1321.2	1203.7	1084.3			5.426	< 0.001
(995.0)	(810.4)	(690.4)	F(2, 70) = 0.470	0.627		
2174.4	2422.7	2196.6		0 4 6 7		
(245.6)	(490.6)	(239.8)	F(2, 35) = 1.885	0.167	F(5, 101) =	. 0. 001
3059.9	3048.9	3243.7		0.205	22.304	< 0.001
(492.9)	(397.4)	(529.9)	F(2, 66) = 1.242	0.295		
39313.1	41231.8	38983.8	5(2, 27) 0,400	0.640		
(5098.6)	(8112.7)	(3769.5)	F(2,37) = 0.488	0.618	F(5, 106) =	. 0. 001
58290.8	58864.5	59950.8		0 700	44.559	< 0.001
(6084.4)	(7178.5)	(8154.6)	F(2, 69) = 0.317	0.729		
1.1210	1.1951	1.1035				
(0.1182)	(0.1799)	(0.0838)	F(2, 35) = 1.537	0.229	F(5, 103) =	
1.2558	1.3006	1.3397			8.983	< 0.001
(0.1750)	(0.1228)	(0.1341)	F(68) = 1.890	0.159		
	s, Males 5 mg 500.6 (449.7) 1321.2 (995.0) 2174.4 (245.6) 3059.9 (492.9) 39313.1 (5098.6) 58290.8 (6084.4) 1.1210 (0.1182) 1.2558 (0.1750)	s, Males 5 mg 10 mg 500.6 407.0 (449.7) (346.2) 1321.2 1203.7 (995.0) (810.4) 2174.4 2422.7 (245.6) (490.6) 3059.9 3048.9 (492.9) (397.4) 39313.1 41231.8 (5098.6) (8112.7) 58290.8 58864.5 (6084.4) (7178.5) 1.1210 1.1951 (0.1182) (0.1799) 1.2558 1.3006 (0.1750) (0.1228)	S, Males S mg 10 mg Placebo 500.6 407.0 518.2 (449.7) (346.2) (321.5) 1321.2 1203.7 1084.3 (995.0) (810.4) (690.4) 2174.4 2422.7 2196.6 (245.6) (490.6) (239.8) 3059.9 3048.9 3243.7 (492.9) (397.4) (529.9) 39313.1 41231.8 38983.8 (5098.6) (8112.7) (3769.5) 58290.8 58864.5 59950.8 (6084.4) (7178.5) (8154.6) 1.1210 1.1951 1.1035 (0.1182) (0.1799) (0.0838) 1.2558 1.3006 1.3397 (0.1750) (0.1228) (0.1341)	s, MalesChanges by5 mg10 mgPlacebo $F(df1, df2)^+$ 500.6407.0518.2 $F(2, 37) = 0.231$ (449.7)(346.2)(321.5) $F(2, 37) = 0.231$ 1321.21203.71084.3 $F(2, 70) = 0.470$ (995.0)(810.4)(690.4) $F(2, 35) = 1.885$ (245.6)(490.6)(239.8) $F(2, 35) = 1.885$ 3059.93048.93243.7 $F(2, 66) = 1.242$ 39313.141231.838983.8 $F(2, 37) = 0.488$ (5098.6)(8112.7)(3769.5) $F(2, 69) = 0.317$ 58290.858864.559950.8 $F(2, 69) = 0.317$ (6084.4)(7178.5)(8154.6) $F(2, 35) = 1.537$ 1.12101.19511.1035 $F(2, 35) = 1.537$ 1.25581.30061.3397 $F(68) = 1.890$ (0.1750)(0.1228)(0.1341) $F(68) = 1.890$	S, Males Changes by sex 5 mg 10 mg Placebo $F(df1, df2)^{\dagger}$ $p-value^{\dagger}$ 500.6 407.0 518.2 $P(2, 37) = 0.231$ 0.795 (449.7) (346.2) (321.5) $P(2, 70) = 0.470$ 0.627 1321.2 1203.7 1084.3 $P(2, 70) = 0.470$ 0.627 (995.0) (810.4) (690.4) $P(2, 35) = 1.885$ 0.167 2174.4 2422.7 2196.6 $P(2, 35) = 1.885$ 0.167 (245.6) (490.6) (239.8) $P(2, 66) = 1.242$ 0.295 3059.9 3048.9 3243.7 $P(2, 66) = 1.242$ 0.295 (492.6) (377.4) (529.9) $P(2, 66) = 1.242$ 0.295 39313.1 41231.8 38983.8 $P(2, 69) = 0.317$ 0.729 (5098.6) (8112.7) (3769.5) $P(2, 69) = 0.317$ 0.729 (5084.4) (7178.5) (8154.6) $P(2, 35) = 1.537$ 0.229 (1.1210) 1.1951 1.1035 $P(2, 35) = 1.537$ </th <th>S, Males Changes by sex Changes b 5 mg 10 mg Placebo $F(df1, df2)^{\dagger}$ p-valuet $F(df1, df2)^{\dagger}$ 500.6 407.0 518.2 $P(2, 37) = 0.231$ 0.795 $P_{F(5, 107) = 1}$ 1321.2 1203.7 1084.3 $P(2, 70) = 0.470$ 0.627 $F(5, 101) = 1$ 1321.2 1203.7 1084.3 $P(2, 70) = 0.470$ 0.627 $P(5, 101) = 1$ 2174.4 2422.7 2196.6 $P(2, 35) = 1.885$ 0.167 $P(5, 101) = 1$ 3059.9 3048.9 3243.7 $P(2, 66) = 1.242$ 0.295 $P(5, 101) = 1$ 3059.9 3048.9 3243.7 $P(2, 66) = 1.242$ 0.295 $P(5, 106) = 1$ 3059.9 3048.9 3243.7 $P(2, 66) = 1.242$ 0.295 $P(5, 106) = 1$ 3059.9 3048.9 3243.7 $P(2, 66) = 0.317$ 0.295 $P(5, 106) = 1$ 39313.1 41231.8 38983.8 $P(2, 69) = 0.317$ 0.729 $P(5, 106) = 1$ 58290.8 58864.5 59950.8 $P(2, 69) = 0.317$ 0.729 $P(5, 103) = 1$ 1.1210</th>	S, Males Changes by sex Changes b 5 mg 10 mg Placebo $F(df1, df2)^{\dagger}$ p-valuet $F(df1, df2)^{\dagger}$ 500.6 407.0 518.2 $P(2, 37) = 0.231$ 0.795 $P_{F(5, 107) = 1}$ 1321.2 1203.7 1084.3 $P(2, 70) = 0.470$ 0.627 $F(5, 101) = 1$ 1321.2 1203.7 1084.3 $P(2, 70) = 0.470$ 0.627 $P(5, 101) = 1$ 2174.4 2422.7 2196.6 $P(2, 35) = 1.885$ 0.167 $P(5, 101) = 1$ 3059.9 3048.9 3243.7 $P(2, 66) = 1.242$ 0.295 $P(5, 101) = 1$ 3059.9 3048.9 3243.7 $P(2, 66) = 1.242$ 0.295 $P(5, 106) = 1$ 3059.9 3048.9 3243.7 $P(2, 66) = 1.242$ 0.295 $P(5, 106) = 1$ 3059.9 3048.9 3243.7 $P(2, 66) = 0.317$ 0.295 $P(5, 106) = 1$ 39313.1 41231.8 38983.8 $P(2, 69) = 0.317$ 0.729 $P(5, 106) = 1$ 58290.8 58864.5 59950.8 $P(2, 69) = 0.317$ 0.729 $P(5, 103) = 1$ 1.1210

Table 3: Dexa baseline output and change after 48 weeks, stratified by sex

Change from baseline – 48 weeks								
	-29.3	-6.1	50 7 (69 3)	F(2,34.546) =	0 287			
Visceral adipose	(170.6)	(116.2)	50.7 (05.5)	1.294	0.207	F(2, 203.934)	0 427	
tissue mass (g)	-48.6	19.2	26.9	F(2. 127.416) =	0 72	= 0.854	0.427	
	(201.0)	(277.4)	(362.6)	0.329	0.72			

Bone mineral	-19.8 (64.4)	-50.6 (106.8)	-23.1 (82.0)	F(2, 43.111) = 0.251	0.779	F(2, 193.245)	0.012
content (g)	-41.7 (95.2)	45.2 (93.3)	-0.7 (100.6)	F(2, 70.240) = 2.249	0.113	= 4.489	0.012
Lean tissue	-60.6 (1613.8)	1939.7 (1998.9)	-298.1 (1191.1)	F(1,70.369) = 1.022	0.004	F(2, 206.447)	0.005
mass (g)	-68.6 (3034.7)	-6.0 (2421.2)	-525.1 (2138.6)	F(2, 80.616) = 0.112	0.894	= 5.439	0.005
Bone Mineral	-0.0114 (0.0195)	-0.0100 (0.0325)	-0.0021 (0.0332)	F(2,43.316) = 1.461	0.243	F(2, 163.750)	0 101
Density (g/cm2)	0.0463 (0.2108)	0.0046 (0.0361)	-0.0012 (0.0267)	F(2, 109.733) = 1.006	0.369	= 1.673	0.191

858 Values provided as mean (standard deviation). Groups were compared using Analysis of Variance (baseline)
859 and linear mixed effects model (change from week 0 through 48) by sex and group.
860

000

Table 4: Baseline SF-36 and WOMAC and absolute change at 48 weeks, stratified by sex

	Women			Men		
	5 mg	10 mg	Placebo	5 mg	10 mg	Placebo
<u>Baseline</u>						
SF-36						
- Physical functioning	95.3 (6.2)	96.1 (4.2)	93.0 (10.7)	94.6 (8.3)	95.6 (9.8)	95.5 (8.7)
- Physical role limitations	92.7 (14.7)	94.4 (11.0)	83.3 (32.3)	94.6 (21.3)	95.4 (12.1)	90.9 (23.8)
- Emotional role	90.2 (22.9)	100.0	97 8 (8 6)	85 5 (26 3)	975(89)	89 / (23 9)
limitations	50.2 (22.5)	(0.0)	57.8 (8.0)	00.0 (20.0)	57.5 (0.5)	05.4 (25.5)
- Energy/fatigue	62.4 (21.3)	65.6 (14.5)	67.7 (22.4)	66.5 (16.9)	73.5 (12.7)	69.6 (13.3)
- Emotional well-being	76.5 (14.6)	76.9 (12.0)	82.4 (10.1)	75.7 (14.3)	85.9 (8.7)	80.4 (11.5)
- Social functioning	92.7 (11.7)	84.7 (27.1)	92.5 (11.4)	92.4 (15.0)	96.3 (8.4)	94.9 (10.7)
- Pain	82.9 (9.9)	74.4 (20.3)	82.3 (18.5)	84.7 (14.7)	87.7 (13.1)	79.4 (18.0)
- General health	77.4 (19.5)	75.6 (17.9)	76.3 (21.2)	75.7 (15.0)	85.0 (15.3)	76.1 (18.3)
- Physical health score	87.1 (9.5)	85.1 (9.9)	83.8 (18.0)	87.4 (12.0)	90.9 (7.8)	85.5 (14.1)
- Mental health score	80.4 (12.1)	81.8 (8.4)	85.1 (10.5)	80.0 (14.0)	88.3 (6.9)	83.6 (11.9)
- Aggregate score	83.7 (10.0)	83.5 (7.3)	84.4 (13.5)	83.7 (10.9)	89.6 (6.3)	84.5 (11.3)
WOMAC						
- Total score (0-96)	28.6 (5.5)	28.7 (6.3)	31.9 (12.6)	29.0 (6.7)	28.2 (8.3)	30.4 (8.1)
- Pain score (0-20)	6.4 (1.8)	6.4 (2.8)	6.7 (2.4)	6.5 (2.2)	6.2 (2.3)	6.1 (1.6)
- Stiffness score (0-8)	3.4 (1.3)	3.2 (1.1)	3.5 (1.6)	2.8 (1.1)	2.7 (1.1)	3.5 (1.2)
- Physical function score (0-68)	18.8 (3.3)	19.0 (4.6)	21.7 (9.0)	19.7 (4.1)	19.3 (5.4)	20.8 (5.9)
Change baseline - 48						
<u>weeks</u>						

SF-36						
- Physical functioning	+0.6 (4.8)	0.0 (6.0)	+0.4 (4.1)	-3.3 (15.3)	-1.6 (6.3)	-0.5 (9.7)
- Physical role limitations	+3.1 (15.5)	+3.1 (8.8)	+5.4 (35.6)	-7.1 (28.7)	-4.0 (22.5)	+0.0 (30.9)
- Emotional role	1 A Q (16 7)	1 2 (11 0)	12 4 (9 0)	1 4 0 (22 0)	0.0 (0.6)	10 2 (25 1)
limitations	+4.2 (10.7)	-4.2 (11.0)	+2.4 (0.9)	+4.0 (55.0)	0.0 (9.0)	+9.5 (25.1)
Enorgy/fatigue	+10.0 (17.4)	+9.4	+2 0 (12 7)	+2 0 (12 7)	+26(99)	+0 2 (0 0)
- Energy/Juligue	+10.0 (17.4)	(12.9)	+2.9 (15.7)	+5.0 (12.7)	+2.0 (0.0)	+0.5 (9.0)
- Emotional well-being	+5.8 (14.2)	+5.0 (9.5)	+4.6 (9.1)	+5.2 (10.4)	+0.8 (5.8)	+3.3 (7.6)
- Social functioning	+3 0 (10 0)	+12.5	±1 8 (12 8)	±2 5 (15 5)	+1 0 (11 4)	1 (Q Q)
- Social junctioning	+3.9 (10.9)	(24.1)	+1.0 (12.0)	+2.5 (15.5)	+1.0 (11.4)	12.1 (0.0)
- Pain	+7.0 (11.9)	+14.7	+1 8 (0 1)	-1 2 (17 8)	-0 9 (8 0)	⊥1 5 (15 2)
- r um	.7.0 (11.5)	(13.9)	1.0 (3.1)	112 (1710)	-0.5 (8.0)	1.5 (15.2)
- General health	+5.3 (12.3)	+5.6	+3.9 (10.2)	+5 8 (8 8)	+2 4 (9 4)	-1.7 (13.0)
General neutin		(12.1)				
- Physical health score	+4.0 (8.0)	+5.9 (5.7)	+2.9 (11.5)	-2.4 (17.9)	-1.0 (7.6)	-0.2 (13.7)
- Mental health score	+6.0 (11.4)	+5.7 (5.9)	+2.9 (7.7)	+4.8 (13.5)	+1.1 (5.3)	+3.7 (8.9)
- Aggregate score	+5.0 (8.9)	+5.8 (4.6)	+2.9 (7.8)	+2.9 (10.3)	+0.0 (5.6)	+1.8 (8.7)
WOMAC						
- Total score (0-96)	-2.3 (5.5)	-3.0 (6.2)	-1.1 (5.1)	-1.0 (4.7)	+2.0 (7.8)	-1.1 (6.6)
- Pain score (0-20)	-0.9 (1.8)	-0.8 (2.9)	+0.4 (2.7)	-0.4 (1.7)	+0.6 (2.4)	-0.3 (1.1)
- Stiffness score (0-8)	-0.7 (1.3)	-0.6 (1.2)	-0.5 (0.9)	-0.2 (1.1)	+0.2 (1.0)	-0.1 (1.2)
- Physical function score	-0.6 (2.4)	-16(5)	-10/22)	-05(27)	±1 2 /E 2)	-07(56)
(0-68)	-0.0 (3.4)	-1.0 (3.2)	-1.0 (3.3)	-0.3 (2.7)	±.2 (J.3)	-0.7 (3.0)

SF-36: short form 36; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index. Values provided as mean (standard deviation).

Supplementary Table S1: Week 48 safety-related blood work assessment								
	5 mg	10 mg	Placebo	F(df1, df2)	p-value			
	N=38	N=33	N=34					
	Mean (SD) *	Mean (SD) *	Mean (SD) *					
Glucose (mg/dL)	91.3 (9.6)	91.8 (8.1)	89.7 (9.5)	F(2, 101) = 0.489	0.614			
LDL cholesterol (mg/dL)	107.9 (34.8)	96.2 (34.1)	103.5 (30.7)	F(2, 102) = 1.095	0.339			
Non-HDL cholesterol (mg/dL)	126.0 (37.6)	116.1 (38.4)	121.3 (32.5)	F(2, 101) = 0.647	0.526			
Triglycerides (mg/dL)	87.1 (33.2)	95.3 (52.1)	84.3 (36.0)	F(2, 102) = 0.659	0.520			
HbA1c (%)	5.2 (0.3)	5.3 (0.3)	5.3 (0.3)	F(2, 102) = 0.961	0.386			
Insulin (uIU/mL)	6.0 (4.7)	7.2 (4.2)	5.5 (3.2)	F(2, 100) = 1.566	0.214			
ALT (U/L)	20.1 (10.4)	25.0 (10.3)	22.0 (10.7)	F(2, 102) = 1.967	0.145			
AST (U/L)	21.7 (6.4)	24.6 (7.4)	23.0 (8.5)	F(2, 102) = 1.355	0.263			
BUN (mg/dL)	17.1 (3.6)	17.2 (3.9)	16.6 (3.9)	F(2, 102) = 0.277	0.759			
Creatinine (mg/dL)	0.9 (0.2)	0.9 (0.2)	1.0 (0.3)	F(2, 102) = 0.597	0.553			
eGFR (mL/min/1.73m ²)	86.3 (13.6)	84.6 (12.3)	81.5 (15.6)	F(2, 98) = 1.026	0.362			

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; BUN: blood urea nitrogen; eGFR: estimated glomerular filtration rate; HbA1c: hemoglobin A1c; HDL: high-density lipoprotein; LDL: low-density lipoprotein; SD: standard deviation. Groups were compared using Analysis of Variance. *p < 0.05

Supplementary Table 52: Baseline Dexa outcomes and absolute change after 48 weeks									
			<u>Baseli</u>	ne					
Dexa Variable	5 mg	10 mg	Placebo	F(df1, df2)	p-value				
Visceral adipose	972.4	1016.2	866.5	F(2, 110) = 0.356	0.701				
tissue mass (g)	(900.2)	(800.4)	(635.9)						
Bone mineral	2680.4	2901.6	2830.4	F(2, 104) = 1.239	0.294				
content (g)	(598.6)	(493.4)	(676.6)						
Lean tissue mass (g)	50018.5	54715.6	51886.5	F(2, 109) = 1.561	0.215				
	(11058.6)	(10518.4)	(12339.9)						
Bone Mineral	1.1996	1.2765	1.2488	F(2,106) = 2.054	0.133				
Density (g/cm2)	(0.1662)	(0.1422)	(0.1644)						
Dexa Variable	Change baseline - 48 weeks								
	5 mg	10 mg	Placebo	F(df1, df2)	p-value				
Visceral adipose	-39.9	+13.1	+35.3	F(2, 101.408) =	0.379				
tissue mass (g)	(185.2)	(246.2)	(290.8)	0.978					
Bone mineral	-31.9	+19.4	-8.7 (93.6)	F(2,104.415) = 1.403	0.250				
content (g)	(8.22)	(104.3)							
Lean tissue mass (g)	-66.0	+517.8	-444.6	F(2,126.996) = 1.115	0.331				
	(2456.0)	(2440.2)	(1838.9)						
Bone Mineral	0.1593	0.0008	-0.0015	F(2,166.294) = 1.596	0.552				
Density (g/cm2)	(0.0097)	0.0352)	(00289)						

Tabl 6.2 . D _ . a h £1.0 10 . . .

Groups were compared using Analysis of Variance (baseline) and linear mixed effects model (change from week 0 through 48). Values provided as mean (standard deviation).

	Baseline				48 weeks				
	5 mg	10 mg	Placebo	p-value	5 mg	10 mg	Placebo	p-value	
SF-36									
- Physical functioning	94.9	95.7	94.5	0.821	-1.6	-1.2 (6.1)	-0.2	0.754	
	(7.4)	(8.7)	(9.5)		(12.0)		(7.7)		
- Physical role limitations	93.8	95.1	87.8	0.263	-2.7	-2.3	+2.3	0.970	
	(18.6)	(11.7)	(27.4)		(24.1)	(20.1)	(32.6)		
- Emotional role	87.5	98.2	92.8	0.054	+4.5	-1.0	+6.3	0.401	
limitations	(24.7)	(7.7)	(19.5)		(27.4)	(10.2)	(19.7)		
- Energy/fatigue	64.8	71.5	68.8	0.209	+6.1	+4.2	+1.4	0.081	
	(18.7)	(13.4)	(17.3)		(15.2)	(10.2)	(11.2)		
- Emotional well-being	76.0	83.7	81.2	0.019	+5.4	+1.8	+3.9	0.479	
	(14.2)	(10.2)	(10.9)		(12.0)	(6.9)	(8.2)		
- Social functioning	92.5	93.4	93.9	0.896	+3.1	+3.8	+1.9	0.745	
	(13.5)	(15.7)	(10.9)		(13.5)	(15.8)	(10.6)		
- Pain	83.9	84.4	80.6	0.528	+2.4	+2.9	+1.6	0.682	
	(12.8)	(16.0)	(18.0)		(15.9)	(11.7)	(12.7)		
- General health	76.4	82.6	76.2	0.203	+5.6	+3.2	+0.8	0.014	
	(16.8)	(16.2)	(19.2)		(10.3)	(10.0)	(12.0)		
- Physical health score	87.2	89.5	84.7	0.254	+0.4	+0.6	+1.2	0.850	
	(10.9)	(8.6)	(15.5)		(14.6)	(7.7)	(12.7)		
- Mental health score	80.2	86.7	84.2	0.037	+5.3	+2.2	+3.4	0.385	
	(13.1)	(7.7)	(11.3)		(12.5)	(5.7)	(8.3)		
- Aggregate score	83.7	88.1	84.5	0.142	+3.8	+1.4	+2.3	0.335	
	(10.4)	(7.0)	(12.0)		(9.6)	(5.9)	(8.2)		
WOMAC									
- Total score (0-96)	28.8	28.3	31.0	0.325	-1.6 (5.0)	+0.8	-1.1	0.325	
	(6.2)	(7.8)	(10.0)			(7.7)	(5.9)		
- Pain score (0-20)	6.5 (2.0)	6.3 (2.4)	6.4 (2.0)	0.900	-0.6 (1.8)	+0.3	0.0 (1.9)	0.184	
						(2.5)			
- Stiffness score (0-8)	3.1 (1.2)	2.9 (1.1)	3.5 (1.4)	0.101	-0.4 (1.2)	0.0 (1.1)	-0.3	0.456	
							(1.1)		

Supplementary Table S3: Baseline SF-36 and WOMAC and absolute change at 48 weeks

- Physical function score	19.3	19.2	21.2	0.220	-0.6 (3.0)	+0.5	-0.8	0.614
(0-68)	(3.7)	(5.1)	(7.2)			(5.3)	(4.6)	

SF-36: short form 36; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index. Values provided as mean (standard deviation).



Time in Weeks

Time in Weeks







а



b



Score Range

Supplementation of the second second



Adverse Event Types



а

b





а







SF-36 QoL Score Changes

